: blastic natural-killer cell lymphoma blastic plasmacytoid dendritic cell neoplasm CD4þCD56þ hematodermic neoplasm a b s t r a c t Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare and highly aggressive hematopoietic malignancy associated with a poor prognosis. It has been recognized to originate from precursors of plasmacytoid dendritic cells and has recently been established as a distinct entity. The most frequent clinical presentations are prominent skin lesions, followed by peripheral blood, bone marrow, and other organ involvement. Treatment outcomes are often disappointing due to a high relapse rate after chemotherapy and risk of leukemic dissemination. Herein, we report a case of BPDCN in a 41-year-old man who presented with cutaneous and nasopharyngeal lesions, and achieved a complete response after systemic chemotherapy. Dermatologists should be aware of BPDCN and its clinical presentations, as early diagnosis with appropriate treatment is crucial to improve its prognosis.
Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previous known as blastic natural-killer (NK) cell lymphoma and CD4þ/ CD56þ hematodermic neoplasm, is a rare and aggressive hematopoietic malignancy with prominent cutaneous involvement and high risk of leukemic disseminations.
1e3 NK cells were previously regarded as the cells of origin of this neoplasm due to the high expression levels of CD56 in patients with CD4þ cutaneous lymphoma and a distinct blastic cytology. 4 However, the lack of other NK-lineage markers, absence of EpsteineBarr virus (EBV) infection, and CD4 expression were not typical of NK cell development in most cases. Therefore, the true NK cell derivation of this tumor was considered controversial. 5 Subsequent studies involving immunophenotypic and functional analyses have shown that the tumor cells are more likely to be derived from precursors of plasmacytoid dendritic cells (pDCs). 6e8 Therefore, BPDCN is regarded as a distinct entity and was categorized among "acute myeloid leukemia and related precursor neoplasm" by the World Health Organization in 2008. 9 We herein report a case of BPDCN with multiple bruise-like skin lesions on the trunk and face at initial presentation.
Case report
A 41-year-old male patient presented with a 1-month history of multiple asymptomatic bruise-like lesions on his trunk and face. Additionally, he developed ecchymotic lesions on the trunk easily from scratching. He also suffered from several episodes of bleeding in the right nasal cavity for 1e2 months. He denied having any underlying systemic disease or malignancy, except for undergoing a cholecystectomy 1 year earlier. On physical examination, we noted multiple 2e3 cm in diameter bluish to violaceous infiltrated patches or plaques scattered on his trunk and a few irregularly shaped violaceous plaques on his cheeks (Figure 1 ). There was neither palpable cervical, axillary, or inguinal superficial lymphadenopathy nor hepatosplenomegaly. He did not experience any episodes of fever, night sweating, or weight loss during this period.
Skin biopsy from his chest revealed diffuse interstitial, perivascular, and periadnexal infiltrations of monotonous mediumsized blastic cells with slightly irregularly shaped nuclei and fine
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The authors declare that they have no financial or nonfinancial conflicts of interest related to the subject matter or materials discussed in this article.chromatin in the dermis. The epidermis was spared with a grenz zone. Neither angiocentrism nor necrosis was present. Erythrocytes extravasation and a few mitotic figures were also present ( Figure 2 ). On immunohistochemical staining, tumor cells were positive for CD4, CD56, and leukocyte common antigen (CD45), and negative for CD3, CD20, CD30, CD45RO, lambda/kappa light chain, epithelial membrane antigen, pancytokeratin (AE1/AE3), and myeloperoxidase. In addition, the tumor cells were also positive for CD123 ( Figure 3) . In situ hybridization for EBV-encoded small nuclear RNA was negative. A biopsy from his right nasopharyngeal tissue also revealed infiltration of diffuse medium-sized lymphoid cells that were positive for CD4, CD56, and CD123 (Figure 4) , and negative for CD3 and EBV-encoded small nuclear RNA.
Laboratory examination showed a normal complete blood cell count with no leukocytosis and no thrombocytopenia. The biochemistry profile, including electrolytes, lactic dehydrogenase, alkaline phosphatase, antinuclear antibody, hepatic and renal function tests, coagulation profile, and urine analysis, was all within normal ranges.
Serology tests for human immunodeficiency virus, rapid plasma regain, hepatitis A/B/C viruses, and human T-cell leukemia virus type I showed negative results. Chest X-ray and cardiac echo revealed no abnormalities. Peripheral blood smear and bone marrow biopsy revealed no conspicuous neoplastic cell infiltrations. Whole body computed tomography revealed thickened soft tissue in his nasopharyngeal mucosa and in both pharyngeal tonsils with no conspicuous lymphadenopathy and no definite distant metastasis.
Based on the typical clinical features, histopathology, and immunohistochemical studies, a diagnosis of BPDCN with skin and nasopharynx involvement was made. The patient was then referred to the hemato-oncology ward to undergo CHOP treatment (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for 3 weeks for a total of eight cycles. After two cycles of CHOP, the bleeding tendency from his nasal cavity stopped. A complete response was achieved after chemotherapy, and the bruise-like infiltrated patches and plaques regressed ( Figure 5A and B). The occurrence of ecchymosis on his body from scratching also diminished during treatment ( Figure 5C ). Follow-up positron emission tomographyecomputed tomography examination revealed no other extracutaneous organ involvement. Finally, the patient was regularly followed-up in our hematology outpatient clinic, and received maintenance therapy of cyclophosphamide and prednisolone.
Discussion
In 1994, Adachi et al 4 The disease mainly affects middle-aged and elderly men (male/ female ratio of 3:1); however, rare congenital and pediatric cases have also been reported. 14, 15 The mean age is 55 years at diagnosis (ranging from 3 days to 96 years), and 76% of the patients are older than 50 years. 16 Skin lesions are the most common manifestation in nearly all BPDCN patients. However, a few cases of patients initially presenting with fulminant leukemia but lacking cutaneous lesions have been reported. 17 Bone marrow and/or peripheral blood and lymph node involvement occurred in 60e90% and 40e50% of patients, respectively. Initial fulminant leukemia is less common (5e 20%), but the risk of leukemic dissemination when tumor progression or relapse is greater and is nearly always present in the terminal stage of BPDCN. According to the literature review, more than half of the patients had only cutaneous lesions at the time of diagnosis. 3 The cutaneous manifestation of BPDCN can be either localized or wide spread. Their appearance is variable and includes violaceous, erythematous, red brown and/or purpuric patches, plaques, nodules, and ulcerative lesions on the head, trunk, and extremities. 9, 18 The bruise-like infiltrated lesions, as observed in our case, could be the early manifestation of neoplastic cell infiltration with red blood cell extravasation in the skin.
The invasion of other mucosal sites is relatively infrequent (about 10%). 1 Other organs, such as the liver, spleen, nasopharynx, tonsils, kidneys, and central nervous system have also been reported to be involved in BPDCN. Systemic B symptoms are rare at diagnosis. 7 Few cases of BPDCN with nasopharyngeal lesions denoted in the literature are often accompanied with lymph node or blood involvement. 3, 19 However, our case showed both skin and nasopharynx involvement, and no conspicuous systemic dissemination. Such clinical manifestations were rarely noted in the literature. This could be explained by the early diagnosis after a 1-month period of skin and nasal manifestations in our case.
Histologically, BPDCN shows diffuse monotonous infiltrates of medium-sized lymphoblastoid cells with round-to-oval nuclei, indistinct nucleoli, scanty cytoplasm, and finely dispersed chromatin, which resemble lymphoblasts or myeloblasts in the dermis and sometimes the subcutis. There is generally no epidermotropism, necrosis, or angioinvasion. The neoplastic cells are often positive for CD4, CD56, CD43, and cutaneous lymphocyteassociated antigen (CLA). 20 Expression levels of terminal deoxynucleotidyl transferase, CD33, CD68, and CD45RA are variable. 3 These neoplastic cells also express the pDC associated antigens CD123, BDCA-2/CD303, and TCL-1, and are negative for common T-cell, B-cell, and myeloid cell lineage markers. 1 It should be noted that some CD4e or CD56e variants have been described for BPDCN. 21 The T-cell receptor gene is germline and rearrangement is nonclonal. It should be differentiated from other blastic hematopoietic malignancies demonstrating positive of CD56 and CD4. 19 The distinction of cases of acute myeloid leukemia/myeloid sarcoma that are CD4þ/CD56þ is difficult. The tumors often express multiple myeloid markers such as myeloperoxidase exclusively, whereas only minorities of them are weakly positive of CD123. 22 Therefore, detection of multiple myeloid markers other than CD33 favors the diagnosis of acute myeloid leukemia/ myeloid sarcoma, whereas expression of multiple plasmacytoid dendritic cell markers favors BPDCN. Extranodal NK/T-cell lymphoma, nasal type is histologically associated with angioinvasion of tumor cells, EBV infection, and the absence of CD123 expression. Myeloid neoplasms with increased pDCs acumination at nodal or extranodal sites often lack CD56 expression and are morphologically mature. In our case, the coexpression of CD4, CD56, and CD123 and lack of EBV infection in the nasal mucosa helped us to clarify whether there is merely an increase in pDC infiltrates in response to immune activation as well as in reactive lymphoid hyperplasia, 7 and to rule out nasal type NK/T-cell lymphoma. The overall prognosis of BPDCN is dismal. The median survival is approximately 12e14 months, and the 5-year-survival rate is 0e6%. 23 The initial clinical presentation of BPDCN may seem deceptively indolent and often responds to multiagent chemotherapy. However, relapse with rapid extracutaneous dissemination, with or without leukemia, occurs in the vast majority of patients with an average disease-free time of 9e11 months. <40 years, high expression of deoxynucleotidyl transferase, presentation of only cutaneous lesions, and aggressive treatment using an acute leukemia protocol are associated with a more favorable prognosis. Our BPDCN case presented with early cutaneous manifestations, including bruise-like lesions, which were accompanied by unusual nasopharyngeal involvement. Although a complete response was observed after initial chemotherapy with regression of nasal and skin lesions, long-term follow-up is necessary due to the high relapse rate, rapid leukemic dissemination, and poor prognosis of the disease. Cutaneous lesions are often the first prominent presentation of BPDCN and show a great variability in their morphologic and phenotypic features. 18 The diagnosis of BPDCN requires exhaustive examination by expert clinicians and histopathologists.
Dermatologists should be aware of the clinical presentations of such hematopoietic neoplasms because the early diagnosis of the disease and appropriate treatment is important to improve the outcome.
